Co-Authors
This is a "connection" page, showing publications co-authored by Alessandro Vannucchi and Alessandro Rambaldi.
Connection Strength
2.132
-
Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
Score: 0.238
-
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
Score: 0.232
-
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
Score: 0.231
-
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 05; 32(5):1200-1210.
Score: 0.188
-
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 10 12; 130(15):1768-1771.
Score: 0.182
-
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. Haematologica. 2017 06; 102(6):e219-e221.
Score: 0.177
-
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017 02 22; 10(1):54.
Score: 0.176
-
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016 09; 91(9):918-22.
Score: 0.169
-
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007 Aug 01; 110(3):840-6.
Score: 0.089
-
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019 08; 8(9):4089-4092.
Score: 0.052
-
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018 09 21; 8(10):89.
Score: 0.049
-
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018 06; 69:100-102.
Score: 0.048
-
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 09; 103(9):e392-e394.
Score: 0.048
-
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. Am J Hematol. 2018 05; 93(5):615-622.
Score: 0.047
-
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018 02 01; 36(4):310-318.
Score: 0.047
-
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res. 2017 12; 63:34-40.
Score: 0.046
-
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017 06 15; 129(24):3227-3236.
Score: 0.044
-
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017 Jan; 92(1):E5-E6.
Score: 0.044
-
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009 Dec; 147(5):681-5.
Score: 0.026